Navigation Links
Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
Date:12/9/2008

NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of Roger G. Stoll, Ph.D. to Delcath's Board of Directors. Dr. Stoll is Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: COR), a biotechnology company specializing in the treatment of central nervous system disorders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Prior to joining Cortex, Dr. Stoll worked as a consultant to several east coast venture capital firms and startup venture companies. From 1998 to 2001, Dr. Stoll was Executive Vice-President of Fresenius Medical Care - North America, a leading manufacturer and distributor of dialysis products, including hemodialysis machines and filters, and operator of more than 1,500 outpatient dialysis clinics in the United States.

From 1991 to 1998, he was President and Chief Executive Officer of Ohmeda, a global pharmaceutical and medical products business. Dr. Stoll was a member of the Board of Directors of the BOC Group, Plc, the parent company of Ohmeda, and also served on the Board of directors of St. Jude Medical. From 1986 to 1991, Dr. Stoll held several executive management positions at Bayer, AG including Executive Vice President and General Manager for the worldwide Diagnostic Business Group. Prior to that, Dr. Stoll worked for American Hospital Supply Corp., where he rose from Director of Clinical Pharmacology to President of the American Critical Care Division. He began his pharmaceutical career at the Upjohn Company, where he conducted human pharmacokinetic and drug metabolism clinical trials on various drugs in all phases of development. He currently serves on the Board of Directors of Chelsea Therapeutics and the School of Pharmacy Advisory Board of the University of Connecticut.

Commenting on today's announcement, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, "As we move closer to the completion of our first Phase III clinical trial, and prepare for commercialization, the addition of the scientific and industry experience of Dr. Stoll will be an invaluable asset to our Company. His specific experiences in the areas of filtration, clinical testing and commercialization will provide important experience and input to projects currently underway at Delcath. We are fortunate that the promise of Delcath's PHP technology and the critical patient need that it addresses enables us to attract such experienced high caliber professionals to our Board."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
2. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Franklin & Seidelmann Adds Richard Dyke to Senior Management Team as Senior VP, Sales/Marketing
6. Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Mark Sutherland Joins GenVault as Senior Vice President, Business Development
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
10. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
11. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute , a ... winners for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, ... one for experiment and the other for theory in nanotechnology. Prof. Markus J. ...
(Date:5/20/2016)... ... ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, in malignant ... Surviving Mesothelioma has just posted an article on the new study. Click here ... study on the fact the Manumycin A, a derivative of Streptomyces parvulus, is known ...
(Date:5/19/2016)... May 19, 2016 There is ... recover given the relentless pressures in pricing and lack ... the investors circle though - numerous opportunities are up ... today,s session, ActiveWallSt.com,s presents four names in this sector: ... Pharmaceuticals Inc. (NASDAQ: VTAE ), Anthera Pharmaceuticals ...
(Date:5/18/2016)... Calif. (PRWEB) , ... May 18, 2016 , ... ... awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last ... company that is financed by one of ACA’s member angel groups. It is the ...
Breaking Biology Technology:
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
Breaking Biology News(10 mins):